Analysis of EFS, OS, and FFS of the randomized trial
| . | Full-dose CPM in second COPADM . | Half-dose CPM in second COPADM . | P . | M1 . | No M1 . | P . |
|---|---|---|---|---|---|---|
| Event | ||||||
| No. | 23 | 29 | — | 26 | 26 | — |
| HR (90% CI) | 1 | 1.27 (0.80-2.0) | .40 | 1 | 1.01 (0.64-1.6) | .98 |
| 4-y EFS rate, % (95% CI) | 93.4 (90-96) | 90.9 (87-94) | — | 91.9 (88-94) | 92.5 (89-95) | — |
| Death | ||||||
| No. | 14 | 21 | — | 19 | 16 | — |
| HR (90% CI) | 1 | 1.56 (0.88-2.8) | .20 | 1 | 0.86 (0.49-1.5) | .66 |
| 4-y survival rate, % (95% CI) | 95.6 (93-97) | 93.6 (90-96) | — | 94.0 (91-96) | 95.2 (92-97) | — |
| Failure | ||||||
| No. | 32 | 36 | — | — | — | — |
| HR (90% CI) | 1 | 1.10 (0.74-1.6) | .70 | — | — | — |
| 4-y FFS rate, % (95% CI) | 90.6 (87-93) | 88.7 (85-92) | — | — | — | — |
| . | Full-dose CPM in second COPADM . | Half-dose CPM in second COPADM . | P . | M1 . | No M1 . | P . |
|---|---|---|---|---|---|---|
| Event | ||||||
| No. | 23 | 29 | — | 26 | 26 | — |
| HR (90% CI) | 1 | 1.27 (0.80-2.0) | .40 | 1 | 1.01 (0.64-1.6) | .98 |
| 4-y EFS rate, % (95% CI) | 93.4 (90-96) | 90.9 (87-94) | — | 91.9 (88-94) | 92.5 (89-95) | — |
| Death | ||||||
| No. | 14 | 21 | — | 19 | 16 | — |
| HR (90% CI) | 1 | 1.56 (0.88-2.8) | .20 | 1 | 0.86 (0.49-1.5) | .66 |
| 4-y survival rate, % (95% CI) | 95.6 (93-97) | 93.6 (90-96) | — | 94.0 (91-96) | 95.2 (92-97) | — |
| Failure | ||||||
| No. | 32 | 36 | — | — | — | — |
| HR (90% CI) | 1 | 1.10 (0.74-1.6) | .70 | — | — | — |
| 4-y FFS rate, % (95% CI) | 90.6 (87-93) | 88.7 (85-92) | — | — | — | — |
HR indicates hazard ratio; —, not applicable.